Loading...
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau, P Pylypenko, H Grosicki, S Karamanesht, L Leleu, X Grishunina, M Rekhtman, G Masliak, Z Robak, T Shubina, A
Moreau, P
Pylypenko, H
Grosicki, S
Karamanesht, L
Leleu, X
Grishunina, M
Rekhtman, G
Masliak, Z
Robak, T
Shubina, A
Citations
Altmetric:
Abstract
Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an important alternative. We compared the efficacy and safety of subcutaneous versus intravenous bortezomib at the approved 1·3 mg/m(2) dose and twice per week schedule in patients with relapsed multiple myeloma.
Description
Date
2011-05
Publisher
Collections
Keywords
Type
Article
Citation
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. 2011, 12 (5):431-40 Lancet Oncol.